Close Menu

NEW YORK – Natera said on Thursday that it is launching a new study, called BESPOKE CRC, for its Signatera cell-free DNA blood test in colorectal cancer patients.

The nationwide multi-center prospective registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer. The test is designed for molecular residual disease assessment, early relapse detection, and patient risk stratification after surgery.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.